AI company Tempus partners with Children’s Oncology Group for pediatric genomic testing

Becker's Healthcare September 21, 2022
Noah Schwartz

Artificial intelligence and precision medicine company Tempus is partnering with the Children’s Oncology Group to study genetic testing-directed treatment in pediatric patients with solid tumors and non-Hodgkin lymphomas and histiocytic disorders.

Tempus will provide genomic sequencing technology to up to 300 patients per year between the ages of 12 months and 21 years. Clinicians will have access to Tempus’ xT assay technology to help identify if patients are eligible for the Children’s Oncology Group’s Pediatric MATCH screening trial, according to the Sept....

Today's Sponsors

Today's Sponsor